Matrix Metalloproteinases Generate Angiostatin: Effects on Neovascularization

Lynn A. Cornelius(Barnes-Jewish Hospital), Leslie Nehring(Barnes-Jewish Hospital), E. A. Harding(Monsanto (United States)), M A Bolanowski(Monsanto (United States)), Howard G. Welgus(Barnes-Jewish Hospital), Dale K. Kobayashi(Barnes-Jewish Hospital), Richard A. Pierce(Barnes-Jewish Hospital), Steven D. Shapiro(Barnes-Jewish Hospital)
The Journal of Immunology
December 1, 1998
Cited by 439Open Access
Full Text

Abstract

Angiostatin, a cleavage product of plasminogen, has been shown to inhibit endothelial cell proliferation and metastatic tumor cell growth. Recently, the production of angiostatin has been correlated with tumor-associated macrophage production of elastolytic metalloproteinases in a murine model of Lewis lung cell carcinoma. In this report we demonstrate that purified murine and human matrix metalloproteinases generate biologically functional angiostatin from plasminogen. Macrophage elastase (MMP-12 or MME) proved to be the most efficient angiostatin-producing MMP. MME was followed by gelatinases and then the stomelysins in catalytic efficiency; interstitial collagenases had little capacity to generate angiostatin. Both recombinant angiostatin and angiostatin generated from recombinant MME-treated plasminogen inhibited human microvascular endothelial cell proliferation and differentiation in vitro. Finally, employing macrophages isolated from MME-deficient mice and their wild-type littermates, we demonstrate that MME is required for the generation of angiostatin that inhibits the proliferation of human microvascular endothelial cells.


Related Papers

No related papers found

Powered by citation graph analysis